医药生物行业周报：脑机接口医疗服务价格单独立项，商业化有望迎来进展

Investment Rating - The report maintains a "Recommended" rating for the healthcare industry, indicating that the industry index is expected to outperform the benchmark index by more than 10% [6]. Core Insights - The healthcare sector has shown a slight outperformance against the CSI 300 index, with the Shenwan Pharmaceutical Bio Index rising by 2.62% from March 10 to March 14, 2025, outperforming the CSI 300 by 1.32 percentage points [1][11]. - Year-to-date, the Shenwan Pharmaceutical Bio Index has increased by 9.14%, surpassing the CSI 300 by 7.25 percentage points, ranking 18th among 31 Shenwan first-level industry indices [1][14]. - As of March 14, 2025, the valuation of the pharmaceutical sector stands at 26.93 times (TTM overall method, excluding negative values), with a premium rate of 132.18% compared to the CSI 300 [1][16]. Summary by Sections Market Performance - The pharmaceutical sector has outperformed the CSI 300 index, with a 2.62% increase during the specified week [1][11]. - The sector's year-to-date performance shows a 9.14% increase, ranking it 18th among all industry indices [1][14]. Key Policies and Events - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Neurological Medical Services (Trial)," which includes pricing for invasive and non-invasive brain-computer interface services, paving the way for clinical application and regulatory compliance [3][22]. Industry Outlook - The establishment of pricing guidelines is expected to promote the development of brain-computer interface technology, enhancing market confidence and attracting investment [4][25]. - The brain-computer interface industry is in its early stages of industrialization, with significant achievements in market scale, company numbers, and technological innovation supported by national and local initiatives [4][26]. - The industry chain includes upstream hardware and software suppliers, midstream product suppliers, and downstream applications, with recommended companies for investment being Guanhao Biological, Maipu Medical, and Seer Medical in the upstream and midstream, and Sanbo Brain Science and Innovation Medical in the downstream [4][26].